SpinaFX Medical receives FDA Investigational Device Exemption (IDE) for Triojection®, its Breakthrough, Minimally-Invasive, Image-Guided Lumbar Disc Treatment.
The prospective, randomized, multicenter trial will compare intradiscal ozone/oxygen injection plus nerve root block to nerve root block alone in 300 patients in up to 30 US sites TORONTO, June 9, 2026 /PRNewswire/ - SpinaFX Medical, a clinical-stage medical device company specializing in...
The prospective, randomized, multicenter trial will compare intradiscal ozone/oxygen injection plus nerve root block to nerve root block alone in 300 patients in up to 30 US sites TORONTO, June 9, 2026 /PRNewswire/ - SpinaFX Medical, a clinical-stage medical device company specializing in...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.